BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.
British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
Origin stories have captivated me ever since my childhood spent reading Greek Mythology and Marvel comic books. Superheroes have different powers and personalities.
Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.
Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.
A number of new reports this month shed new light on old issues in Gout.
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein).
Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found.
Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
